BACKGROUND: The sulfamide (R(2)NSO(2)NR(2)) functionality is an acceptable functional group in medicinal chemistry when incorporated into putative small-molecule therapeutics, as it has the potential to form several electrostatic interactions with protein and other targets. The clinically-useful broad spectrum antibiotic doripenem contains a mono-substituted sulfamide. The sulfamide functional group is often found to substitute for sulfonamide, sulfamate or urea functionality. OBJECTIVE/ METHOD: During the period of 2006-2008, there were nine published patents in which all or most reported compounds contained the sulfamide functional group. There are also patents in which the structures disclosed contain a cyclic sulfamide functional group. Further, there are patents published during this timeframe that contain only a few sulfamide-containing examples, typically as a bioisosteric replacement for a sulfonamide moiety. In this review, we focus on those published patents in which most compounds disclosed are sulfamides and only briefly highlight examples in which sulfamides are included among a large list of other suitable functionalities. CONCLUSION: While the sulfamide functionality is still fairly under-represented in medicinal chemistry, it is a valuable and versatile group that will gain increasing acceptance and favor in the future.
BACKGROUND: The sulfamide (R(2)NSO(2)NR(2)) functionality is an acceptable functional group in medicinal chemistry when incorporated into putative small-molecule therapeutics, as it has the potential to form several electrostatic interactions with protein and other targets. The clinically-useful broad spectrum antibiotic doripenem contains a mono-substituted sulfamide. The sulfamide functional group is often found to substitute for sulfonamide, sulfamate or urea functionality. OBJECTIVE/ METHOD: During the period of 2006-2008, there were nine published patents in which all or most reported compounds contained the sulfamide functional group. There are also patents in which the structures disclosed contain a cyclic sulfamide functional group. Further, there are patents published during this timeframe that contain only a few sulfamide-containing examples, typically as a bioisosteric replacement for a sulfonamide moiety. In this review, we focus on those published patents in which most compounds disclosed are sulfamides and only briefly highlight examples in which sulfamides are included among a large list of other suitable functionalities. CONCLUSION: While the sulfamide functionality is still fairly under-represented in medicinal chemistry, it is a valuable and versatile group that will gain increasing acceptance and favor in the future.
Authors: Hongjian Lu; Chaoqun Li; Huiling Jiang; Christopher L Lizardi; X Peter Zhang Journal: Angew Chem Int Ed Engl Date: 2014-05-19 Impact factor: 15.336
Authors: Jung Ho Jun; Vineet Kumar; Thomas S Dexheimer; Iwona Wedlich; Marc C Nicklaus; Yves Pommier; Sanjay V Malhotra Journal: Eur J Pharm Sci Date: 2017-10-13 Impact factor: 4.384
Authors: Bogdan Barnych; Natalia Vasylieva; Tom Joseph; Susan Hulsizer; Hai M Nguyen; Tomas Cajka; Isaac Pessah; Heike Wulff; Shirley J Gee; Bruce D Hammock Journal: Chemistry Date: 2017-05-30 Impact factor: 5.236